CN101732440B - Raspberry extract, raspberry element separated from raspberry extract and application of raspberry element - Google Patents
Raspberry extract, raspberry element separated from raspberry extract and application of raspberry element Download PDFInfo
- Publication number
- CN101732440B CN101732440B CN2009102011334A CN200910201133A CN101732440B CN 101732440 B CN101732440 B CN 101732440B CN 2009102011334 A CN2009102011334 A CN 2009102011334A CN 200910201133 A CN200910201133 A CN 200910201133A CN 101732440 B CN101732440 B CN 101732440B
- Authority
- CN
- China
- Prior art keywords
- raspberry
- extract
- group
- raspberry extract
- osteoporosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 235000011034 Rubus glaucus Nutrition 0.000 title claims abstract description 109
- 235000009122 Rubus idaeus Nutrition 0.000 title claims abstract description 109
- 240000007651 Rubus glaucus Species 0.000 title claims abstract description 97
- 239000000284 extract Substances 0.000 title claims abstract description 75
- 244000235659 Rubus idaeus Species 0.000 title description 12
- 208000001132 Osteoporosis Diseases 0.000 claims abstract description 16
- 210000003734 kidney Anatomy 0.000 claims abstract description 15
- 206010018367 Glomerulonephritis chronic Diseases 0.000 claims abstract description 12
- 208000031975 Yang Deficiency Diseases 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 9
- 229940079593 drug Drugs 0.000 claims abstract description 5
- 239000000126 substance Substances 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 21
- 238000002360 preparation method Methods 0.000 claims description 18
- 239000007864 aqueous solution Substances 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 6
- 229940023569 palmate Drugs 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 238000005325 percolation Methods 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000012675 alcoholic extract Substances 0.000 claims description 3
- 235000013399 edible fruits Nutrition 0.000 claims description 2
- 238000007654 immersion Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 241000123889 Rubus chingii Species 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 abstract description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 9
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 229930002330 retinoic acid Natural products 0.000 description 7
- 229960003604 testosterone Drugs 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 description 5
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 229960000890 hydrocortisone Drugs 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 201000008350 membranous glomerulonephritis Diseases 0.000 description 5
- 229960001566 methyltestosterone Drugs 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 210000000689 upper leg Anatomy 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229920001615 Tragacanth Polymers 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- 239000000305 astragalus gummifer gum Substances 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 4
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 4
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 235000011869 dried fruits Nutrition 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000012353 t test Methods 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 229960001727 tretinoin Drugs 0.000 description 3
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 0 OC1=Cc(c(O)c(C(C*2)=O)c2c2O)c2OC1=O Chemical compound OC1=Cc(c(O)c(C(C*2)=O)c2c2O)c2OC1=O 0.000 description 2
- 206010041497 Spermatorrhoea Diseases 0.000 description 2
- DCSBSVSZJRSITC-UHFFFAOYSA-M alendronate sodium trihydrate Chemical compound O.O.O.[Na+].NCCCC(O)(P(O)(O)=O)P(O)([O-])=O DCSBSVSZJRSITC-UHFFFAOYSA-M 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000002021 butanolic extract Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000002072 distortionless enhancement with polarization transfer spectrum Methods 0.000 description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 2
- 238000003929 heteronuclear multiple quantum coherence Methods 0.000 description 2
- 229960002591 hydroxyproline Drugs 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- JUJWROOIHBZHMG-RALIUCGRSA-N pyridine-d5 Chemical compound [2H]C1=NC([2H])=C([2H])C([2H])=C1[2H] JUJWROOIHBZHMG-RALIUCGRSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- XILIYVSXLSWUAI-UHFFFAOYSA-N 2-(diethylamino)ethyl n'-phenylcarbamimidothioate;dihydrobromide Chemical compound Br.Br.CCN(CC)CCSC(N)=NC1=CC=CC=C1 XILIYVSXLSWUAI-UHFFFAOYSA-N 0.000 description 1
- -1 6-substituted benzene rings Chemical group 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- ZWLYQTAJHFUKFZ-UHFFFAOYSA-N CC(C(CC1)C2C1=O)C(C)C(CC(C(C)=C)O)C2O Chemical compound CC(C(CC1)C2C1=O)C(C)C(CC(C(C)=C)O)C2O ZWLYQTAJHFUKFZ-UHFFFAOYSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 206010018372 Glomerulonephritis membranous Diseases 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229960004343 alendronic acid Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003262 anti-osteoporosis Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000002596 lactones Chemical group 0.000 description 1
- 231100000855 membranous nephropathy Toxicity 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- ZQKOGDIJTMNWCT-UFQCMFJCSA-N methyltestosterone group Chemical group CC1[C@@H]2[C@]([C@H](C1)O)(C)CC[C@H]1[C@H]2CCC2=CC(=O)CC[C@]12C ZQKOGDIJTMNWCT-UFQCMFJCSA-N 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 206010036596 premature ejaculation Diseases 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及医药技术领域,是从掌叶覆盆子(Rubus chingii Hu)中提取的覆盆子提取物及从中分离得到的覆盆子素以及它们在制备治疗和预防慢性肾炎、肾阳虚和骨质疏松药物中的应用。覆盆子素化学结构式如下:本发明覆盆子提取物及覆盆子素具有防治慢性肾炎、肾阳虚和骨质疏松的活性,因而可以用于制备治疗和预防慢性肾炎、肾阳虚或骨质疏松的药物。The present invention relates to the field of medical technology, and is a raspberry extract extracted from Rubus chingii Hu and raspberry extract isolated therefrom, as well as their use in preparing drugs for treating and preventing chronic nephritis, kidney yang deficiency and osteoporosis. The chemical structure of raspberry extract is as follows: The raspberry extract and raspberry element of the invention have the activity of preventing and treating chronic nephritis, kidney yang deficiency and osteoporosis, and can be used for preparing medicine for treating and preventing chronic nephritis, kidney yang deficiency or osteoporosis.
Description
技术领域 technical field
本发明涉及医药技术领域,是从掌叶覆盆子(Rubus chingii Hu)中提取的覆盆子提取物及从中分离得到的覆盆子素以及它们在制备治疗和预防慢性肾炎、肾阳虚或骨质疏松药物中的应用。The invention relates to the technical field of medicine, and relates to raspberry extract extracted from Rubus chingii Hu and raspberry extract isolated therefrom and their preparation for treating and preventing chronic nephritis, kidney yang deficiency or osteoporosis application in medicine.
背景技术 Background technique
覆盆子(Fructus rubi)为蔷薇科悬钩子属植物掌叶覆盆子(Rubus chingii Hu)的干燥近成熟果实。甘、酸,温。归肾、膀胱经。益肾,固精,缩尿。用于肾虚遗尿,小便频数,阳痿早泄,遗精滑精等症。覆盆子在我国资源丰富,主要分布于浙江、江苏、安徽、江西、福建、广西等地,在《中国药典》已收载。近年来,国内外对覆盆子已有一定研究,向德军报道,覆盆子提取物具有一定温肾助阳作用(广东药学院学报2002.18(3):217-218),但未提及其活性成分。到目前为止,也未见覆盆子提取物具有防治慢性肾炎、肾阳虚或骨质疏松的报道。Raspberry (Fructus rubi) is the dry near-ripe fruit of Rubus chingii Hu in the family Rosaceae. Sweet, sour, warm. Return kidney, urinary bladder channel. Tonifying the kidney, strengthening essence, reducing urination. For enuresis due to kidney deficiency, frequent urination, impotence and premature ejaculation, spermatorrhea and spermatorrhea embolism. Raspberry is rich in resources in my country, mainly distributed in Zhejiang, Jiangsu, Anhui, Jiangxi, Fujian, Guangxi and other places, and it has been recorded in "Chinese Pharmacopoeia". In recent years, there has been some research on raspberry at home and abroad, and it was reported to the German army that raspberry extract has a certain effect of warming the kidney and helping yang (Journal of Guangdong Pharmaceutical University 2002.18(3): 217-218), but did not mention its active ingredients . So far, there is no report that raspberry extract can prevent and treat chronic nephritis, kidney yang deficiency or osteoporosis.
发明内容 Contents of the invention
本发明提供一种具有防治慢性肾炎、骨质疏松活性的覆盆子提取物及从覆盆子提取物中分离得到的新化合物-覆盆子素。覆盆子素的化学结构式为:The invention provides a raspberry extract with the activity of preventing and treating chronic nephritis and osteoporosis and a new compound-raspberry element isolated from the raspberry extract. The chemical structural formula of raspberry element is:
本发明研究表明,覆盆子素为覆盆子提取物的活性成分,具有防治慢性肾炎、骨质疏松和肾阳虚的活性。The research of the present invention shows that the raspberry element is the active ingredient of the raspberry extract, and has the activity of preventing and treating chronic nephritis, osteoporosis and kidney-yang deficiency.
本发明覆盆子提取物及覆盆子素的制备方法如下:The preparation method of raspberry extract of the present invention and raspberry element is as follows:
1.制备覆盆子提取物1. Preparation of Raspberry Extract
将掌叶覆盆子干燥果实用0-95%乙醇水溶液按常规渗漉提取或浸泡提取,优选用50-80%乙醇水溶液提取,最佳为70%乙醇水溶液,提取液减压浓缩至无醇味的浸膏,得覆盆子提取物;Extract the dried fruit of raspberry palmate with 0-95% ethanol aqueous solution according to conventional percolation or soaking extraction, preferably with 50-80% ethanol aqueous solution, most preferably with 70% ethanol aqueous solution, and concentrate the extract under reduced pressure until it has no alcohol smell The extract, raspberry extract;
2.制备覆盆子素粗制品2. Preparation of crude raspberry extract
将上述覆盆子提取物用水稀释后依次用石油醚、二氯甲烷萃取,弃萃取液,然后用水饱和正丁醇萃取,将正丁醇萃取液减压浓缩,得覆盆子素粗制品;Dilute the above-mentioned raspberry extract with water, then extract with petroleum ether and dichloromethane in sequence, discard the extract, then extract with saturated n-butanol with water, concentrate the n-butanol extract under reduced pressure to obtain a crude raspberry element;
3.分离提取覆盆子素3. Separation and extraction of raspberry element
将上述覆盆子素粗制品用水混悬,上大孔树脂D101,依次分别用水、30%、60%和95%乙醇水溶液洗脱,收集30%乙醇洗脱液,减压浓缩成浸膏状并用甲醇溶解,用硅胶H(60型,青岛海洋化工集团公司)拌样,上硅胶H层析柱,以氯仿-甲醇(30∶1-1∶1)溶剂系统洗脱,收集氯仿-甲醇5∶1的洗脱液,并浓缩,用甲醇清洗后得黄色粉末,也即覆盆子素。Suspend the above crude product of raspberry extract with water, apply it to macroporous resin D101, and then elute with water, 30%, 60% and 95% ethanol aqueous solution respectively, collect the 30% ethanol eluate, concentrate under reduced pressure into extract and use Dissolve in methanol, mix the sample with silica gel H (type 60, Qingdao Ocean Chemical Group Co., Ltd.), put it on a silica gel H chromatography column, and elute with chloroform-methanol (30:1-1:1) solvent system to collect chloroform-methanol 5: 1, and concentrated, washed with methanol to obtain a yellow powder, that is, raspberry element.
经动物实验,本发明覆盆子提取物及覆盆子素具有防治慢性肾炎、肾阳虚和骨质疏松的活性,因此可用于制备防治慢性肾炎、肾阳虚和骨质疏松的药物。According to animal experiments, the raspberry extract and raspberry element of the present invention have the activity of preventing and treating chronic nephritis, deficiency of kidney yang and osteoporosis, so they can be used to prepare medicines for preventing and treating chronic nephritis, deficiency of kidney yang and osteoporosis.
本发明提取物和覆盆子素化合物制备方法简单,成本低廉,本发明为防治慢性肾炎、肾阳虚和骨质疏松提供了一种新的药物来源。The preparation method of the extract and the raspberry element compound of the invention is simple and low in cost, and the invention provides a new drug source for preventing and treating chronic nephritis, kidney-yang deficiency and osteoporosis.
具体实施方式:Detailed ways:
现结合实施例对本发明作详细描述。The present invention is described in detail in conjunction with embodiment now.
所用的掌叶覆盆子是2007年9月采集于浙江杭州的掌叶覆盆子。The raspberry palmate used was collected in September 2007 in Hangzhou, Zhejiang.
实施例1.制备覆盆子提取物Example 1. Preparation of raspberry extract
掌叶覆盆子干燥果实50kg,用水溶液按常规渗漉提取,提取液减压浓缩至无醇味的浸膏,得覆盆子提取物12.6kg。50 kg of dried fruit of raspberry palmate was extracted by percolation with an aqueous solution as usual, and the extract was concentrated under reduced pressure to a non-alcoholic extract to obtain 12.6 kg of raspberry extract.
实施例2.制备覆盆子提取物Example 2. Preparation of raspberry extract
掌叶覆盆子干燥果实50kg,用95%溶液按常规渗漉提取,提取液减压浓缩至无醇味的浸膏,得覆盆子提取物2.4kg。50 kg of dried fruit of raspberry palmate was extracted by percolation with a 95% solution as usual, and the extract was concentrated under reduced pressure to an alcohol-free extract to obtain 2.4 kg of raspberry extract.
实施例3.制备覆盆子提取物Example 3. Preparation of raspberry extract
掌叶覆盆子干燥果实50kg,用70%乙醇水溶液按常规渗漉提取,提取液减压浓缩至无醇味的浸膏,得覆盆子提取物6.5kg。50 kg of dried fruit of raspberry palmate was extracted by percolation with 70% ethanol aqueous solution as usual, and the extract was concentrated under reduced pressure to a non-alcoholic extract to obtain 6.5 kg of raspberry extract.
实施例4.用覆盆子提取物制备覆盆子素Embodiment 4. prepare raspberry element with raspberry extract
1.制备覆盆子素粗制品1. Preparation of crude raspberry extract
将实施例3制备的覆盆子提取物用水稀释至体积为50L,先用50L石油醚分别萃取3次,弃萃取液,再用50L二氯甲烷萃取3次,弃萃取液,然后用水饱和正丁醇萃取3次,每次50L,合并正丁醇萃取液,减压浓缩,得覆盆子素粗制品。The raspberry extract prepared in Example 3 was diluted with water to a volume of 50L, first extracted 3 times with 50L petroleum ether, discarded the extract, then extracted 3 times with 50L dichloromethane, discarded the extract, then saturated with n-butyl ether Alcohol extraction 3 times, 50 L each time, combined n-butanol extracts, concentrated under reduced pressure to obtain crude raspberry element.
2.分离提取覆盆子素2. Separation and extraction of raspberry element
将上述覆盆子素粗制品用水混悬,上大孔树脂D101,依次用水、30%、60%和95%乙醇水溶液洗脱,收集30%乙醇洗脱液,减压浓缩成浸膏状并用甲醇溶解,用硅胶H(60型,青岛海洋化工集团公司)拌样,上硅胶H层析柱,以氯仿-甲醇(30∶1-1∶1)溶剂系统洗脱,收集氯仿-甲醇5∶1的洗脱液,并浓缩,用甲醇清洗后得黄色粉末,也即覆盆子素。Suspend the above-mentioned raspberry extract crude product with water, apply it to macroporous resin D101, elute with water, 30%, 60% and 95% ethanol aqueous solution in sequence, collect the 30% ethanol eluate, concentrate under reduced pressure into an extract and wash with methanol Dissolve, mix the sample with silica gel H (type 60, Qingdao Ocean Chemical Group Co., Ltd.), put it on a silica gel H chromatography column, elute with chloroform-methanol (30:1-1:1) solvent system, collect chloroform-methanol 5:1 The eluate was concentrated and washed with methanol to obtain a yellow powder, that is, raspberry element.
结构鉴定:Structure Identification:
黄色粉末,m.p.:267-269℃,ESI-MS:m/z 247[M-H]-,确定化合物分子量为248,HR-MS显示分子式为:C12H8O6。UV(EtOH):λmax(ε)=364(10143),299(28317),200(17918)。IR(KBr):vO-H=3404cm-1,vC=O=1684cm-1,vC=C=1599cm-1,vCH2=1392cm-1,vC-O=1305cm-1。Yellow powder, mp: 267-269°C, ESI-MS: m/z 247[MH] - , the molecular weight of the compound is determined to be 248, and the molecular formula shown by HR-MS is: C 12 H 8 O 6 . UV (EtOH): λmax (ε) = 364 (10143), 299 (28317), 200 (17918). IR(KBr): v OH = 3404 cm -1 , v C = O = 1684 cm -1 , v C = C = 1599 cm -1 , v CH2 = 1392 cm -1 , v CO = 1305 cm -1 .
1H-NMR(400MHz,δ,pyridine-d5)中,1HNMR信号δ=2.5(2H,m),δ=3.5(2H,m),显示有-CH2-CH2-,δ=8.0(1H,s),显示为双键上的H。13C-NMR中的信号δ=195.5和δ=160.5,显示有一个α,β-不饱和酮和α,β-不饱和酯的存在。从13C-NMR谱和DEPT谱中可知该化合物中含有9个季C、1个-CH、2个-CH2,13C-NMR中110-150有6个峰,DEPT谱中显示6个峰均为季C,表示有6取代苯环存在。In 1 H-NMR (400MHz, δ, pyridine-d5), 1 HNMR signal δ=2.5(2H, m), δ=3.5(2H, m), showed -CH 2 -CH 2 -, δ=8.0( 1H, s), shown as H on the double bond. Signals δ=195.5 and δ=160.5 in 13 C-NMR indicated the presence of an α,β-unsaturated ketone and α,β-unsaturated ester. From 13 C-NMR spectrum and DEPT spectrum, it can be seen that the compound contains 9 quaternary C, 1 -CH, 2 -CH 2 , 110-150 in 13 C-NMR has 6 peaks, and DEPT spectrum shows 6 peaks The peaks are all quaternary C, indicating the presence of 6-substituted benzene rings.
综合以上信息可以推断该化合物为苯环,一边连一个六元内酯环,一边连五元酮环,另两个C被OH取代。Based on the above information, it can be deduced that the compound is a benzene ring, one side is connected with a six-membered lactone ring, the other side is connected with a five-membered ketone ring, and the other two Cs are replaced by OH.
依据HMQC谱可以对该化合物的碳氢作进一步的归属。According to the HMQC spectrum, the hydrocarbons of the compound can be further assigned.
在HMQC谱中,δ=23.8的仲C对应δ=3.5(2H,m)的H,δ=33.0的仲C对应δ=2.5(2H,m)的H,δ=108.0的季C对应δ=8.0(1H,s)的H。HMBC中,δ=8.0的H与δ=160.5,140.1,144.2,149.3,113.2的C相关,说明双键分别与酯键和苯环相连,δ=2.5的H与δ=141.1,195.5,23.8的C相关,说明此CH2与酮羰基相连,δ=3.5的H与δ=141.1,145.0,195.5,23.8的C相关,说明两个CH2相连,并且后者连于苯环上。各型号归属如表1所示。In the HMQC spectrum, the secondary C of δ = 23.8 corresponds to the H of δ = 3.5 (2H, m), the secondary C of δ = 33.0 corresponds to the H of δ = 2.5 (2H, m), and the quaternary C of δ = 108.0 corresponds to δ = 8.0 H of (1H, s). In HMBC, H of δ=8.0 is related to C of δ=160.5, 140.1, 144.2, 149.3, and 113.2, indicating that the double bonds are connected to ester bonds and benzene rings respectively, H of δ=2.5 is related to C of δ=141.1, 195.5, and 23.8 C is related, indicating that this CH 2 is connected to the ketone carbonyl, and H of δ=3.5 is related to C of δ=141.1, 145.0, 195.5, and 23.8, indicating that two CH 2 are connected, and the latter is connected to the benzene ring. The assignment of each model is shown in Table 1.
综合以上分析,确定该化合物的完整结构,命名为覆盆子素,其结构式为:Based on the above analysis, the complete structure of the compound is determined, named as raspberry element, and its structural formula is:
表1.覆盆子素的1H、13C-NMR数据(400MHz,δ,pyridine-d5)Table 1. 1 H, 13 C-NMR data of raspberry (400MHz, δ, pyridine-d5)
药理、药效实验Pharmacology, efficacy experiment
本发明覆盆子提取物与覆盆子素的药理或药效学实验方法基本相同,现详述如下:Raspberry extract of the present invention is basically the same as the pharmacology or pharmacodynamics experimental method of raspberry element, now detailed as follows:
一、覆盆子提取物与覆盆子素对大鼠被动型Heymann肾炎的防治作用1. Prevention and treatment effect of raspberry extract and raspberry element on passive Heymann nephritis in rats
被动型Heymarm肾炎是研究人类膜性肾病的经典模型,以大量蛋白尿为显著特征[中华肾脏病杂志.1999.15(3):158]。因此,本发明用Heymann肾炎模型研究覆盆子提取物及覆盆子素对肾炎的防治作用。Passive Heymarm nephritis is a classic model for studying human membranous nephropathy, which is characterized by massive proteinuria [Chinese Journal of Nephrology. 1999.15(3): 158]. Therefore, the present invention uses the Heymann nephritis model to study the prevention and treatment effect of raspberry extract and raspberry element on nephritis.
1、试验材料1. Test material
1.1、实验仪器1.1. Experimental Instruments
BCA蛋白检测试剂盒(Pierce公司,美国),ReverTra DashTM试剂盒(Toyobo公司,日本)。BCA protein detection kit (Pierce company, the United States), ReverTra DashTM kit (Toyobo company, Japan).
1.2、供试样品:1.2. Samples for testing:
覆盆子提取物(实施例3制备)Raspberry extract (prepared in Example 3)
覆盆子素(实施例4制备,纯度均不小于93.2%,下同);Raspberry element (prepared in embodiment 4, the purity is not less than 93.2%, the same below);
地塞米松(河北冀衡药业有限公司)Dexamethasone (Hebei Jiheng Pharmaceutical Co., Ltd.)
临用时将覆盆子提取物、覆盆子素和地塞米松分别用0.5%的羧甲基纤维素钠(CMCNa)混配制成相应浓度。Before use, the raspberry extract, raspberry element and dexamethasone were mixed with 0.5% carboxymethylcellulose sodium (CMCNa) respectively to prepare corresponding concentrations.
2、试验动物2. Test animals
品系:Wistar大鼠Strain: Wistar rat
性别:雄性Gender: male
体重:175~200克Weight: 175-200 grams
来源:中科院上海动物中心(下同)Source: Shanghai Animal Center, Chinese Academy of Sciences (the same below)
动物合格证:沪动合证字005号Animal certificate: Shanghai Donghe Zhengzi No. 005
饲养:恒温净化通风动物房,自由进食与饮水,25±2℃。Breeding: constant temperature, purified and ventilated animal room, free access to food and water, 25±2°C.
3、试验方法3. Test method
3.1制备抗FX1A血清3.1 Preparation of anti-FX1A serum
1)制备FX1A抗原1) Preparation of FX1A antigen
正常雄性Wistar大鼠,乙醚麻醉后消毒皮肤,剪开胸腹腔,以无菌的冷生理盐水灌洗肾脏,然后分离肾皮质称重,将皮质充分研磨成匀浆后加适量生理盐水,依次用80目、100目和220目筛网过滤,收集最后的滤液,将滤液以1600r/min20min离心,取上清,重复离心一次,取上清,再以10000r/min 30min离心后弃上清,将沉淀物用双蒸水洗涤3次,所得沉淀物为FXA1A抗原。For normal male Wistar rats, disinfect the skin after ether anesthesia, cut open the chest and abdomen cavity, lavage the kidney with sterile cold saline, then separate the renal cortex and weigh it, grind the cortex into a homogenate, add appropriate amount of saline, and use Filter through 80 mesh, 100 mesh and 220 mesh sieves, collect the final filtrate, centrifuge the filtrate at 1600r/min for 20min, take the supernatant, repeat the centrifugation once, take the supernatant, then centrifuge at 10000r/min for 30min, discard the supernatant, and put The precipitate was washed 3 times with double distilled water, and the obtained precipitate was FXA1A antigen.
2)制备抗FX1A血清2) Preparation of anti-FX1A serum
将上述制备的FXA1A抗原和等体积弗氏完全佐剂充分乳化后,间隔2周经皮下免疫大耳白兔,共免疫6次后取血清。用免疫双向扩散和间接免疫荧光法测定效价,分别达到1∶32和1∶2000为合格。颈动脉取血,分离血清,其为抗FX1A血清,-20℃备用,使用前灭活。After fully emulsifying the above-prepared FXA1A antigen and an equal volume of complete Freund's adjuvant, large-eared white rabbits were subcutaneously immunized at intervals of 2 weeks, and the serum was collected after 6 times of immunization. The titer was determined by two-way immunodiffusion and indirect immunofluorescence, and the titer was 1:32 and 1:2000 respectively. Blood was collected from the carotid artery, and serum was separated, which was anti-FX1A serum, kept at -20°C for use, and inactivated before use.
3.2、被动型Heymann肾炎模型的建立和动物分组3.2. Establishment of passive Heymann nephritis model and animal grouping
取雄性Wistar大鼠75只,它们的24h尿蛋白均小于10mg。随机平均分为5组:阳性对照组、覆盆子提取物组、覆盆子素组、模型对照组(简称模型组,下同)和空白对照组(简称空白组,下同)。空白组一次性尾静脉注射生理盐水5ml/kg;其余各组大鼠一次性尾静脉注射抗FX1A血清5ml/kg进行造模,在造模当天起每天经口灌胃给药(给药剂量分别以每公斤体重计算),共4周,给药剂量分别为阳性对照组(地塞米松,0.1mg/kg/d);覆盆子提取物组(30g/kg/d);覆盆子素组(10mg/kg/d);模型组和空白组每天每只大鼠经口灌注0.5%的羧甲基纤维素钠(CMCNa)混悬液5mg/kg/d。Seventy-five male Wistar rats were taken, and their 24-h urine protein was less than 10 mg. Randomly divided into 5 groups on average: positive control group, raspberry extract group, raspberry element group, model control group (abbreviated model group, the same below) and blank control group (abbreviated blank group, the same below). The blank group was injected with normal saline 5ml/kg into the tail vein at one time; the rats in the other groups were injected with 5ml/kg of anti-FX1A serum through the tail vein at one time to establish the model. Calculation per kilogram of body weight), totally 4 weeks, administration dosage is respectively positive control group (dexamethasone, 0.1mg/kg/d); Raspberry extract group (30g/kg/d); Raspberry element group ( 10 mg/kg/d); the model group and the blank group were orally perfused with 0.5% carboxymethylcellulose sodium (CMCNa) suspension 5 mg/kg/d every day.
3.3、观察指标3.3. Observation indicators
尿蛋白定量采用BCA(bicinchoninincacid)法,5个组均在造模开始第2和第4周周末分别放入代谢笼中,收集24h尿液。计量资料以均数±标准差(x±SD)表示,各组分别与模型组比较,采用双侧两样本t检验进行统计分析。结果见表2。Urinary protein was quantified using the BCA (bicinchoninnacid) method. All five groups were placed in metabolic cages at the end of the second and fourth weeks of modeling, and urine was collected for 24 hours. The measurement data are expressed as mean ± standard deviation (x±SD). Each group was compared with the model group, and the two-sided two-sample t test was used for statistical analysis. The results are shown in Table 2.
表2.大鼠尿蛋白量统计表Table 2. Statistical table of urine protein in rats
与模型组比较:**P<0.01Compared with the model group: **P<0.01
由表2可见,覆盆子提取物和覆盆子素尿蛋白量明显低于模型组(P<0.05),接近于阳性对照组,说明本发明覆盆子提取物和覆盆子素对被动型Heymann肾炎具有显著疗效。Visible by table 2, raspberry extract and raspberry element urine protein amount are obviously lower than model group (P<0.05), close to positive control group, illustrate that raspberry extract of the present invention and raspberry element have positive effect on passive Heymann's nephritis. Significant curative effect.
二、覆盆子提取物、覆盆子素对氢化可的松诱导的小鼠肾阳虚的防治作用2. Prevention and treatment effect of raspberry extract and raspberry element on hydrocortisone-induced kidney-yang deficiency in mice
本发明选用了氢化可的松诱导的小鼠肾阳虚模型,此模型是经典的、常用的肾阳虚模型。The present invention selects the mouse model of kidney-yang deficiency induced by hydrocortisone, which is a classic and commonly used model of kidney-yang deficiency.
1、试验材料1. Test material
1.1、造模药品1.1. Drugs for modeling
名称:氢化可的松Name: Hydrocortisone
来源:天津市生物化学制药厂Source: Tianjin Biochemical Pharmaceutical Factory
含量:50mg/瓶Content: 50mg/bottle
性状:注射用粉针Properties: powder for injection
配制:用生理盐水配成3.57mg/ml。Preparation: use physiological saline to make 3.57mg/ml.
1.2、供试样品:1.2. Samples for testing:
覆盆子提取物、覆盆子素同上;甲睾酮片(上海信谊康捷药业有限公司);金匮肾气丸(北京同仁堂科技发展股份有限公司制药厂)。Raspberry extract and raspberry element are the same as above; Methyltestosterone Tablets (Shanghai Xinyi Kangjie Pharmaceutical Co., Ltd.); Jinkuishenqi Pills (Beijing Tongrentang Science and Technology Development Co., Ltd. Pharmaceutical Factory).
配制溶液:临用时将覆盆子提取物、覆盆子素溶于1%西黄蓍胶制成相应浓度的混悬液;Solution preparation: before use, dissolve raspberry extract and raspberry element in 1% tragacanth gum to make a suspension of corresponding concentration;
甲睾酮:用1%西黄蓍胶制成30mg/ml的混悬液;Methyltestosterone: use 1% tragacanth gum to make a 30mg/ml suspension;
金匮肾气丸:用1%西黄蓍胶制成150mg/kg的混悬液。Jinkuishenqi Pills: use 1% tragacanth gum to make a 150mg/kg suspension.
2、试验动物2. Test animals
品系:ICR小鼠Strain: ICR mice
年龄:6周龄Age: 6 weeks old
级别:清洁级Level: clean level
性别:雄性Gender: Male
体重:25g±2gWeight: 25g±2g
来源:上海斯莱克实验动物责任有限公司Source: Shanghai Slack Experimental Animal Co., Ltd.
动物合格证号:SCXK(沪)2007-0005Animal certificate number: SCXK (Shanghai) 2007-0005
饲养:清洁级动物房,自由进食与进水,温度:25±2℃,湿度:40-60%,人工照明模拟昼夜变化。Breeding: clean animal room, free access to food and water, temperature: 25±2°C, humidity: 40-60%, artificial lighting to simulate diurnal changes.
3、试验方法3. Test method
雄性ICR小鼠64只,在实验条件下适应3天。随机分组,每组8只。除空白组每天每只小鼠腹腔注射0.2ml生理盐水连续注射10天外,其余各组每天每只小鼠腹腔注射0.2ml氢化可的松溶液造模,同时分别灌胃上述配制的药液,给药剂量为:覆盆子提取物低剂量组10g/kg;覆盆子提取物高剂量组30g/kg;覆盆子素低剂量组5mg/kg;覆盆子素高剂量组10mg/kg;甲睾酮组0.65g/kg;金匮肾气丸组6g/kg;模型组和空白组分别灌胃0.5ml 1%西黄蓍胶,并连续注射氢化可的松溶液10天。给药第13天,各组小鼠称重,眼眶取血,然后处死小鼠。摘取小鼠的睾丸、肾脏,称重。小鼠血液放置2小时后,离心,取血清,放置在-20℃冰箱中,待测。Sixty-four male ICR mice were adapted to the experimental conditions for 3 days. Randomly grouped, 8 in each group. Except for the blank group, each mouse was intraperitoneally injected with 0.2ml of normal saline every day for 10 days, and each mouse of the other groups was injected with 0.2ml of hydrocortisone solution every day to establish a model, and at the same time, the above-mentioned prepared medicinal solution was administrated into the stomach respectively. Dosage: raspberry extract low dose group 10g/kg; raspberry extract high dose group 30g/kg; raspberry extract low dose group 5mg/kg; raspberry extract high dose group 10mg/kg; methyltestosterone group 0.65 g/kg; Jinkuishenqi pill group 6g/kg; model group and blank group were given 0.5ml 1% tragacanth gum and injected hydrocortisone solution continuously for 10 days. On the 13th day after the administration, the mice in each group were weighed, blood was collected from the orbit, and then the mice were sacrificed. The testes and kidneys of the mice were removed and weighed. After the mouse blood was left for 2 hours, it was centrifuged, and the serum was collected and placed in a -20°C refrigerator for testing.
各组小鼠肾脏和睾丸重量无差异,血清样品使用睾酮化学发光试剂盒,按照使用说明操作,测定血清睾酮浓度。计算每组小鼠体重和睾酮浓度的平均值和标准差(n=8),实验数据用x±SD表示,各组分别与模型组比较,采用双侧两样本t检验进行统计分析,结果见表3。There was no difference in the weights of the kidneys and testes of the mice in each group. The testosterone chemiluminescence kit was used for serum samples, and the serum testosterone concentration was determined according to the instructions. Calculate the mean and standard deviation (n=8) of each group of mouse body weight and testosterone concentration, the experimental data is represented by x ± SD, each group is compared with the model group respectively, adopts two-sided two-sample t test to carry out statistical analysis, the results are shown in table 3.
表3小鼠的体重及睾酮浓度水平统计表Table 3 Statistical table of body weight and testosterone concentration level of mice
与模型组比较:*P<0.05,**P<0.01Compared with the model group: *P<0.05, **P<0.01
由表3可见,模型组小鼠体重明显低于空白组,血液睾酮水平较空白组有非常显著的差异(P<0.01)。本发明覆盆子提取物和覆盆子素组,体重接近空白组和甲睾酮及金匮肾气丸组;血液睾酮水平与甲睾酮及金匮肾气丸组接近,特别是覆盆子提取物和覆盆子素高剂量组,血液睾酮水平基本与空白组和甲睾酮及金匮肾气丸组持平,与模型组相比有显著性差异(P<0.01)。结果表明,本发明覆盆子提取物和覆盆子素对小鼠肾阳虚具有明显的防治作用。It can be seen from Table 3 that the body weight of the mice in the model group was significantly lower than that of the blank group, and the blood testosterone level was significantly different from that of the blank group (P<0.01). Raspberry extract and raspberry element group of the present invention, body weight is close to blank group and methyltestosterone and Jinkuishenqi pill group; blood testosterone level is close to methyltestosterone and Jinkuishenqi pill group, especially raspberry extract and raspberry The level of blood testosterone in the high-dose group of Penzisu was basically the same as that of the blank group, methyltestosterone and Jinkuishenqiwan group, and had a significant difference compared with the model group (P<0.01). The results show that the raspberry extract and raspberry element of the present invention have obvious prevention and treatment effects on mice with kidney-yang deficiency.
三、覆盆子提取物和覆盆子素对维甲酸致小鼠骨质疏松的治疗作用3. Therapeutic effect of raspberry extract and raspberry element on retinoic acid-induced osteoporosis in mice
为了研究覆盆子提取物和覆盆子素的抗骨质疏松的作用,本实验采用维甲酸致骨质疏松的动物模型,因为全反式维甲酸是一种免疫抑制剂,其具有抑制骨合成等作用,所以常用来建立动物骨质疏松模型。In order to study the anti-osteoporosis effect of raspberry extract and raspberry element, this experiment adopts the animal model of retinoic acid-induced osteoporosis, because all-trans retinoic acid is an immunosuppressant, which can inhibit bone synthesis, etc. Therefore, it is often used to establish animal models of osteoporosis.
1、试验材料1. Test material
1.1、实验仪器1.1. Experimental Instruments
AE240电子天平(梅特勒-托利多仪器公司)。AE240 electronic balance (Mettler-Toledo Instruments).
1.2、供试样品:1.2. Samples for testing:
覆盆子提取物和覆盆子素同上;全反式维甲酸(河南中天实业有限公司);阿仑膦酸钠(华北制药公司)。Raspberry extract and raspberry element are the same as above; all-trans retinoic acid (Henan Zhongtian Industrial Co., Ltd.); alendronate sodium (North China Pharmaceutical Company).
配制:临用时将覆盆子提取物、覆盆子素、全反式维甲酸和阿仑膦酸钠分别溶于0.5%的羧甲基纤维素钠(CMCNa)混悬液中待用。Preparation: before use, the raspberry extract, raspberry element, all-trans retinoic acid and sodium alendronate were respectively dissolved in 0.5% carboxymethylcellulose sodium (CMCNa) suspension for use.
羟脯氨酸(HOP)检测试剂盒(南京建成生物工程研究所)。Hydroxyproline (HOP) detection kit (Nanjing Jiancheng Bioengineering Institute).
2、试验动物2. Test animals
品系:昆明种小鼠Strain: Kunming mouse
性别:雄性Gender: male
体重:33±4克Weight: 33±4 grams
来源:中科院上海动物中心Source: Shanghai Animal Center, Chinese Academy of Sciences
动物合格证:沪动合证字005号Animal certificate: Shanghai Donghe Zhengzi No. 005
饲养:恒温净化通风动物房,自由进食与饮水,25±2℃。Breeding: constant temperature, purified and ventilated animal room, free access to food and water, 25±2°C.
3、试验方法3. Test method
昆明种小鼠40只,随机分成4组,每组10只:分别为空白组,模型组,覆盆子提取物组(30g/kg),覆盆子素组(10mg/kg)。除空白组外,其余各组均用全反式维甲酸(105mg/kg)造模,每天上午灌胃给药维甲酸,下午灌胃给予小鼠相应剂量的药物,模型组和空白组分别灌胃0.5%的羧甲基纤维素钠(CMCNa)混悬液,共14天。实验过程中每周周末称体重一次,第15天处死动物,并取右股骨供测定用。40 Kunming mice were randomly divided into 4 groups, 10 in each group: blank group, model group, raspberry extract group (30g/kg), and raspberry element group (10mg/kg). Except for the blank group, all the other groups were modeled with all-trans retinoic acid (105 mg/kg). Retinoic acid was intragastrically administered every morning, and mice were given corresponding doses of drugs by intragastric administration in the afternoon. The model group and the blank group were administered respectively. Stomach 0.5% carboxymethylcellulose sodium (CMCNa) suspension for 14 days. During the experiment, the body weight was weighed once every weekend, and the animals were sacrificed on the 15th day, and the right femur was taken for measurement.
小鼠股骨剖取后,剔除附着的软组织,经80℃烘干至恒重,并进行如下测定:After the mouse femur was dissected, the attached soft tissue was removed, dried at 80°C to constant weight, and measured as follows:
(1)骨干重测量:用电子天平称量,得骨干重;(1) backbone weight measurement: weigh with an electronic balance to get the backbone weight;
(2)骨长度基骨横径测量:用游标卡尺对股骨长度及横径进行测量;(2) Measurement of bone length and transverse diameter of the base bone: measure the length and transverse diameter of the femur with a vernier caliper;
实验结果以均数±标准差(x±SD)表示,计量资料用t检验进行组间比较。The experimental results were expressed as mean ± standard deviation (x ± SD), and the measurement data were compared between groups by t test.
结果见表4。The results are shown in Table 4.
表4小鼠的体重及骨指数统计表Table 4 Statistical table of body weight and bone index of mice
与模型组比较:*P<0.05,**P<0.01;与模型组比较:#P<0.05,##P<0.01Compared with the model group: *P<0.05, **P<0.01; compared with the model group: #P<0.05, ##P<0.01
由表4可见,模型组小鼠右股骨干重及右股骨横短径均显著小于空白组,而覆盆子提取物或覆盆子素组均显著高于模型组(P<0.05,P<0.01)。说明覆盆子提取物或覆盆子素对骨质疏松症具有防治作用。As can be seen from Table 4, the dry weight of the right femur and the transverse short diameter of the right femur in the model group were significantly smaller than the blank group, while the raspberry extract or raspberry element group were significantly higher than the model group (P<0.05, P<0.01) . It shows that raspberry extract or raspberry element has preventive effect on osteoporosis.
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009102011334A CN101732440B (en) | 2009-12-15 | 2009-12-15 | Raspberry extract, raspberry element separated from raspberry extract and application of raspberry element |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009102011334A CN101732440B (en) | 2009-12-15 | 2009-12-15 | Raspberry extract, raspberry element separated from raspberry extract and application of raspberry element |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101732440A CN101732440A (en) | 2010-06-16 |
CN101732440B true CN101732440B (en) | 2012-05-30 |
Family
ID=42456808
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009102011334A Expired - Fee Related CN101732440B (en) | 2009-12-15 | 2009-12-15 | Raspberry extract, raspberry element separated from raspberry extract and application of raspberry element |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101732440B (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103284143B (en) * | 2012-03-31 | 2014-10-08 | 蔡晓鹏 | Rubus chingii decoction piece and preparation method thereof |
CN102987548B (en) * | 2012-12-05 | 2014-09-17 | 陕西中烟工业有限责任公司 | Plant extract capable of reducing harmful substances in cigarette and preparation method thereof |
CN103316024B (en) * | 2013-06-18 | 2015-03-04 | 中国人民解放军第二军医大学 | Application of labdane diterpene glycoside compounds in rubus chingii Hu as medicine |
CN103623082B (en) * | 2013-11-29 | 2016-08-17 | 江西中医药大学 | Fructus Rubi extract and application thereof |
CN107353273B (en) * | 2017-07-17 | 2019-12-03 | 抚州市东乡区九鼎牧业有限公司 | The method of luteolin and Rubus corchorifolius element is extracted from Rubus corchorifolius |
-
2009
- 2009-12-15 CN CN2009102011334A patent/CN101732440B/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN101732440A (en) | 2010-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101732440B (en) | Raspberry extract, raspberry element separated from raspberry extract and application of raspberry element | |
CN102107006A (en) | Coupling medicament for treating diabetes mellitus and medicinal application thereof | |
CN101279964A (en) | Guaiacane-type sesquiterpene, its preparation method and its medicinal use | |
CN103508919B (en) | Alkaloid compound and preparing the purposes in anticomplement medicament | |
TWI320714B (en) | Plant extracts for the treatment of rheumatoid arthritis | |
CN102579519B (en) | Extracts of total saponins of pterocephalus hookeri and preparation method and application thereof | |
CN104940479A (en) | TCM composition for treating AD diseases | |
CN103316024B (en) | Application of labdane diterpene glycoside compounds in rubus chingii Hu as medicine | |
CN103405487A (en) | Chinese medicine compound effective part with effect of treating arthritis | |
CN113827629A (en) | Application of folium Artemisiae Argyi in treating and preventing stomach diseases caused by helicobacter pylori | |
CN103417630B (en) | Extract of litsea citrata root and applications thereof | |
CN102793729A (en) | Triptolide and chinese brake herb general flavone combined medicinal composition and preparation and application thereof | |
CN106822095B (en) | A kind of medicine for preventing and treating fatty liver and obesity and its application in pharmacy | |
CN102274268A (en) | Traditional Chinese medicine active extract with temperance function, and preparation method and application thereof | |
CN103118688B (en) | Herba Cynomorii chemical composition is as the novelty teabag of phytoestrogen | |
CN105194346B (en) | Traditional Chinese medicine composition with weight loss effect and preparation method thereof | |
CN104370716A (en) | Phenolic compound preparation method and application thereof | |
CN108635352A (en) | Magnoflorine is in the Use and preparation method for preparing prevention insomnia antidepressant agents | |
CN103301134A (en) | Pharmaceutical composition for treating hyperlipidemia as well as preparation method and applications | |
CN101564453A (en) | Medicine for treating chronic nonspecific ulcerative colitis and preparation method thereof | |
CN107485613B (en) | Application of Calycosin Derivatives in Preparation of Drugs for Treating Cerebral Ischemia-Reperfusion Injury | |
Hu et al. | Raspberry ameliorates renal fibrosis in rats with chronic kidney disease via the PI3K/Akt pathway | |
CN101167816B (en) | preparation method of total glycosides of ranunculus and application thereof | |
CN105884841B (en) | A kind of preparation method of phenylpropanoids | |
CN105732736B (en) | A kind of preparation method of phenylpropanoids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120530 Termination date: 20141215 |
|
EXPY | Termination of patent right or utility model |